Description
Denik Pharm OTOTROPIN (HGH) is a high-purity lyophilised powder formulated for advanced research and performance applications. Each kit contains 20 IU per vial (5 vials total), ensuring consistent quality and reliable results. Supplied with a 2 ml sterile water ampoule for convenient reconstitution, this product is manufactured under strict quality standards to maintain stability, potency, and purity.
| Contents | hGH (191aa Human Growth Hormone) lyophilised powder 20iu x 5 vials Ampoule: 2ml Sterile water for injection. |
| Administration | Intramuscular or Subcutaneous injection. |
| Storage | Store at room temperature away from heat and direct sunlight pre reconstitution. Refrigerate between 2-8’C post Reconstitution. |
| Dosage | Adult: SC Growth hormone deficiency Initial: 6 mcg/kg/day. May increase dose gradually. Max: 12.5 mcg/kg/day. HIV-associated wasting or cachexia 0.1 mg/kg/day at bedtime. May take on alternate days for patients at increased risk of adverse effects. Max: 6 mg/day. Short bowel syndrome100 mcg/kg/day for 4 wk. Max: 8 mg/day. |
| Contraindications | Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment. |
| Special Precautions | Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis. |
| Adverse Drug Reactions | Hypothyroidism, peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics. |
| Drug Interactions | High doses of corticosteroid may inhibit growth-promoting effects of somatropin. |
| Pregnancy Category (US FDA) | Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters). |
| ATC Classification | H01AC01 – somatropin ; |
| Disclaimer | “Images displayed on the website are for representational purposes only which may differ from the actual purchased product. The company may change or alter the packaging design without notice.” |
Reviews
There are no reviews yet.